Cargando…
A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer
BACKGROUND: Programmed cell death-1 (PD-1) immune checkpoint inhibitor antibody has proven to be effective in advanced non-small cell lung cancer (NSCLC) patients positive for programmed cell death-1 ligand-1 (PD-L1). However, there are currently no prospective studies evaluating PD-L1 expression fo...
Autores principales: | Tsunoda, Akihito, Morikawa, Kei, Inoue, Takeo, Miyazawa, Teruomi, Hoshikawa, Masahiro, Takagi, Masayuki, Mineshita, Masamichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555021/ https://www.ncbi.nlm.nih.gov/pubmed/31174496 http://dx.doi.org/10.1186/s12885-019-5773-3 |
Ejemplares similares
-
Differences in skeletal muscle loss caused by cytotoxic chemotherapy and molecular targeted therapy in patients with advanced non‐small cell lung cancer
por: Kakinuma, Kazutaka, et al.
Publicado: (2017) -
Drastic healing process after pembrolizumab monotherapy in a case of advanced squamous cell carcinoma with severe bronchial stenosis observed over a two‐year period using continuous bronchoscopy: A case report
por: Morikawa, Kei, et al.
Publicado: (2020) -
Probe‐based confocal laser endomicroscopy for rapid on‐site evaluation of transbronchial biopsy specimens
por: Takemura, Masao, et al.
Publicado: (2019) -
Drug-induced Hypersensitivity Syndrome by EGFR-TKI in a Patient with Lung Cancer
por: Oyama, Baku, et al.
Publicado: (2021) -
Severe tracheal stenosis with tracheopathia osteoplastica-like changes due to traumatic blunt injury
por: Kakinuma, Kazutaka, et al.
Publicado: (2014)